<DOC>
	<DOCNO>NCT00610363</DOCNO>
	<brief_summary>This clinical research study determine safety effectiveness experimental drug call rilonacept subject gout begin another additional treatment . Subjects participate study approximately 24 week . Rilonacept study use prevent gout attack patient gout .</brief_summary>
	<brief_title>Study Safety Effectiveness Rilonacept Prevention Gout Flares</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<criteria>Male female great 18 year age Previously meet preliminary criterion ARA classification acute arthritis primary gout At least 2 gout flare year prior Screening Visit Acute gout flare within 2 week Screening visit Screening Persistent chronic active infection History allergic reaction allopurinol History presence cancer within 5 year Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>